Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2007

01-06-2007 | Laboratory Investigation

Ocular penetration of caspofungin in a rabbit uveitis model

Authors: David Goldblum, Kathrin Fausch, Beatrice E. Frueh, Regula Theurillat, Wolfgang Thormann, Stefan Zimmerli

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2007

Login to get access

Abstract

Background

Little is known about the ocular penetration of echinocandin antifungals. We studied the ocular distribution of systemically administered caspofungin in a rabbit uveitis model.

Methods

Caspofungin (1 mg/kg per day) was given intravenously to rabbits as a single dose or as repeated daily doses on 7 days starting 24 h after induction of unilateral uveitis by intravitreal endotoxin injection. Caspofungin concentrations were determined by high-performance liquid chromatography in the cornea, aqueous humor, vitreous humor, and serum 4, 8, 16, and 24 h after administration of a single dose and 24 h after the last of seven doses.

Results

The mean caspofungin concentration in the aqueous of the inflamed eye 4 and 8 h after single-dose administration was 1.30 ± 0.39 μg/ml and 1.12 ± 0.34 μg/ml, respectively. Drug concentrations decreased to 0.24 ± 0.09 μg/ml at 16 h and 0.26 ± 0.14 μg/ml at 24 h. In the vitreous of inflamed eyes drug levels were undetectable at all time points. No drug was found in the aqueous of inflamed eyes 24 h after the last of seven repeated doses, and the vitreous only contained trace amounts. In the corneas of inflamed eyes concentrations reached 1.64 ± 0.48 μg/g at 4 h, peaked at 2.16 ± 1.14 μg/g at 8 h, and declined to 1.87 ± 0.52 μg/g and 1.49 ± 0.48 μg/g at 16 and 24 h, respectively. After repeated dosing, corneal concentrations of caspofungin were 0.8 and 1.0 μg/g and below the limit of detection in  two of four animals. In non-inflamed eyes no drug was detectable in the aqueous and vitreous humor, and the corneas at any time point.

Conclusions

In our model, caspofungin reached therapeutically relevant levels in the aqueous and cornea but not in the vitreous humor of inflamed eyes. Intraocular drug deposition was critically dependent on a disrupted blood-eye barrier. These findings suggest a limited role for caspofungin in the treatment of fungal endophthalmitis.
Literature
1.
go back to reference Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46:451–457PubMedCrossRef Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46:451–457PubMedCrossRef
2.
go back to reference Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG (2005) Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 139:135–140PubMedCrossRef Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG (2005) Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 139:135–140PubMedCrossRef
3.
go back to reference Chavez-Eng CM, Schwartz M, Constanzer ML, Matuszewski BK (1999) Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 721:229–238PubMedCrossRef Chavez-Eng CM, Schwartz M, Constanzer ML, Matuszewski BK (1999) Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 721:229–238PubMedCrossRef
4.
go back to reference Cornely OA, Schmitz K, Aisenbrey S (2002) The first echinocandin: caspofungin. Mycoses 45(Suppl)3:56–60PubMed Cornely OA, Schmitz K, Aisenbrey S (2002) The first echinocandin: caspofungin. Mycoses 45(Suppl)3:56–60PubMed
6.
go back to reference Durand ML, Kim IK, D’Amico DJ, Loewenstein JI, Tobin EH, Kieval SJ, Martin SS, Azar DT, Miller FS 3rd, Lujan BJ, Miller JW (2005) Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 140:552–554PubMedCrossRef Durand ML, Kim IK, D’Amico DJ, Loewenstein JI, Tobin EH, Kieval SJ, Martin SS, Azar DT, Miller FS 3rd, Lujan BJ, Miller JW (2005) Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 140:552–554PubMedCrossRef
7.
go back to reference Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ (1994) Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar d-mannitol and serum galactomannan as markers of infection. J Infect Dis 169:356–368PubMed Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ (1994) Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar d-mannitol and serum galactomannan as markers of infection. J Infect Dis 169:356–368PubMed
8.
go back to reference Gauthier GM, Nork TM, Prince R, Andes D (2005) Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41:e27–e28PubMedCrossRef Gauthier GM, Nork TM, Prince R, Andes D (2005) Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41:e27–e28PubMedCrossRef
9.
go back to reference Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S (2005) Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother 49:1359–1363PubMedCrossRef Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S (2005) Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother 49:1359–1363PubMedCrossRef
10.
go back to reference Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S (2002) Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 46:3719–3723PubMedCrossRef Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S (2002) Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 46:3719–3723PubMedCrossRef
11.
go back to reference Groll AH, Gullick BM, Petraitiene R, Petraitis V, Candelario M, Piscitelli SC, Walsh TJ (2001) Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 45:596–600PubMedCrossRef Groll AH, Gullick BM, Petraitiene R, Petraitis V, Candelario M, Piscitelli SC, Walsh TJ (2001) Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 45:596–600PubMedCrossRef
12.
go back to reference Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H (1997) Preliminary animal pharmacokinetics of the parenteral antifungal agent mk-0991 (L-743,872). Antimicrob Agents Chemother 41:2339–2344PubMed Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H (1997) Preliminary animal pharmacokinetics of the parenteral antifungal agent mk-0991 (L-743,872). Antimicrob Agents Chemother 41:2339–2344PubMed
13.
go back to reference Kulkarni PS, Mancino M (1993) Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res 56:275–279PubMedCrossRef Kulkarni PS, Mancino M (1993) Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res 56:275–279PubMedCrossRef
14.
go back to reference Levin LA, Avery R, Shore JW, Woog JJ, Baker AS (1996) The spectrum of orbital aspergillosis: a clinicopathological review. Surv Ophthalmol 41:142–154PubMedCrossRef Levin LA, Avery R, Shore JW, Woog JJ, Baker AS (1996) The spectrum of orbital aspergillosis: a clinicopathological review. Surv Ophthalmol 41:142–154PubMedCrossRef
15.
go back to reference Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL (2005) Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49:5058–5068PubMedCrossRef Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL (2005) Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49:5058–5068PubMedCrossRef
16.
go back to reference Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029PubMedCrossRef Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029PubMedCrossRef
17.
go back to reference Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, Pearson PG (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48:1272–1280PubMedCrossRef Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, Pearson PG (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48:1272–1280PubMedCrossRef
18.
go back to reference Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM (2005) Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 40:e46-e48PubMedCrossRef Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM (2005) Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 40:e46-e48PubMedCrossRef
19.
go back to reference Schwartz M, Kline W, Matuszewski B (1997) Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal Chim Acta 352:299–307CrossRef Schwartz M, Kline W, Matuszewski B (1997) Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal Chim Acta 352:299–307CrossRef
20.
go back to reference Srinivasan R, Kanungo R, Goyal JL (1991) Spectrum of oculomycosis in south India. Acta Ophthalmol (Copenh) 69:744–749CrossRef Srinivasan R, Kanungo R, Goyal JL (1991) Spectrum of oculomycosis in south India. Acta Ophthalmol (Copenh) 69:744–749CrossRef
21.
go back to reference Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407–3411PubMedCrossRef Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407–3411PubMedCrossRef
22.
go back to reference Stevens DA, White TC, Perlin DS, Selitrennikoff CP (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51:173–178PubMedCrossRef Stevens DA, White TC, Perlin DS, Selitrennikoff CP (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51:173–178PubMedCrossRef
23.
go back to reference Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC (2004) Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815–823PubMedCrossRef Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC (2004) Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815–823PubMedCrossRef
24.
go back to reference Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529–1535PubMedCrossRef Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529–1535PubMedCrossRef
25.
go back to reference Walsh TJ, Bacher J, Pizzo PA (1988) Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 38:467–471PubMed Walsh TJ, Bacher J, Pizzo PA (1988) Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 38:467–471PubMed
26.
go back to reference Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402PubMedCrossRef Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402PubMedCrossRef
27.
go back to reference Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE (2004) Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190:1464–1471PubMedCrossRef Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE (2004) Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190:1464–1471PubMedCrossRef
28.
go back to reference Yohai RA, Bullock JD, Aziz AA, Markert RJ (1994) Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39:3–22PubMedCrossRef Yohai RA, Bullock JD, Aziz AA, Markert RJ (1994) Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39:3–22PubMedCrossRef
Metadata
Title
Ocular penetration of caspofungin in a rabbit uveitis model
Authors
David Goldblum
Kathrin Fausch
Beatrice E. Frueh
Regula Theurillat
Wolfgang Thormann
Stefan Zimmerli
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-006-0460-x

Other articles of this Issue 6/2007

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2007 Go to the issue